menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Emerging HDL Therapies: What’s Next on the Clinical Research Horizon

ReachMD Healthcare Image
Restart
Resume
Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Comments
  • Overview

    Host Dr. Alan Brown welcomes Benjamin Ansell, MD, professor of medicine and cardiology at University of Califronia at Los Angeles, CA and co-director of the Cholesterol and Hypertension Management Program at UCLA. Dr. Ansell reviews the latest trials: dal-OUTCOMES and AIM-HIGH. Dr. Ansell will address the objectives and study designs of both studies and explain why the studies were stopped early. Drs. Brown and Ansell also discuss the future of HDL therapy.


    Brought to you by:

    NLA logo

     

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    Host Dr. Alan Brown welcomes Benjamin Ansell, MD, professor of medicine and cardiology at University of Califronia at Los Angeles, CA and co-director of the Cholesterol and Hypertension Management Program at UCLA. Dr. Ansell reviews the latest trials: dal-OUTCOMES and AIM-HIGH. Dr. Ansell will address the objectives and study designs of both studies and explain why the studies were stopped early. Drs. Brown and Ansell also discuss the future of HDL therapy.


    Brought to you by:

    NLA logo

     

Facebook Comments

Schedule25 Apr 2024